Journal of travel medicine
-
Randomized Controlled Trial
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine.
Chikungunya disease, caused by chikungunya virus (CHIKV), is associated with substantial morbidity, including debilitating CHIKV-related arthralgia. ⋯ A single dose of VLA1553 presented with an excellent local tolerability profile and overall safety in line with that expected for a live-attenuated vaccine. The safety profile was comparable in participants aged 18-64 years and ≥65 years.
-
In a cohort of patients treated with oral artemisinin combination therapy for uncomplicated malaria, the presence of anti-red blood cell (RBC) auto-antibodies does not correlate with the extent of post-treatment haemolysis. Patients with positive antibody screening test on d14 had higher initial parasitaemia and a higher number of once-infected RBCs throughout follow-up.